Copenhagen, Denmark—As a second-line treatment for hepatocellular carcinoma (HCC) after progression on sorafenib, the tyrosine kinase inhibitor regorafenib significantly improves overall survival (OS), according to results of a Phase III trial. These data were joined by a new analysis from a previously published, negative, Phase III trial of second-line HCC treatment that also suggested a potential OS benefit with the monoclonal antibody ramucirumab in selected patient groups.
Both sets